“…The results of our study are strengthened by the findings of other five randomized clinical trials, that compared a doublet chemotherapy with a single chemotherapeutic agent as second line therapy of patients affected by NSCLC [28][29][30][31][32]. Namely, three trials compared 3-weekly docetaxel with a combination of docetaxel and gemcitabine [28] or docetaxel and irinotecan [29,30].…”